Clinical Trial Update: The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain [Phase 2]

View source ↗

Summary

Phase 2 study of OK-101 for neuropathic corneal pain has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Corneal Pain

Drugs mentioned

• OK-101

Snippet

Sponsor: Okyo Pharma Ltd | Conditions: Neuropathic Pain | Phase 2 | Status: TERMINATED